Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Apr;75(Suppl 1):644-646.
doi: 10.1007/s13224-024-02083-4. Epub 2025 Feb 1.

The Role of Adalimumab in Recurrent Pregnancy Loss Due Immune Dysregulation: A Case Series Report

Affiliations
Case Reports

The Role of Adalimumab in Recurrent Pregnancy Loss Due Immune Dysregulation: A Case Series Report

Aruna Rajan et al. J Obstet Gynaecol India. 2025 Apr.

Abstract

Tumor necrosis factor-alpha, a multifunctional T-helper 1 (Th1) cytokine, plays a significant role in placentation and embryonic development. Altered expression of TNF-α has been implicated in adverse pregnancy outcomes such as recurrent pregnancy loss (RPL) and pre-eclampsia (PE). The use of TNF-α inhibitors (TNFi) like Adalimumab (AD) has garnered attention for its ability to traverse the placental barrier, and modulating maternal immune responses during pregnancy. In this article, we have discussed two patients in whom the immunological factors have been identified in otherwise unexplained RPL and how the use of TNFi could be of help to achieve a viable pregnancy.

Keywords: Adalimumab; Autoimmune; Recurrent pregnancy loss (RPL); Tumor necrosis factor alpha blocker TNFi.

PubMed Disclaimer

Conflict of interest statement

Conflict of interestThe authors declare no conflict of interest.

Similar articles

References

    1. Truta B, Canner JK, Fang SH, et al. Outcomes of continuation vs discontinuation of adalimumab therapy during third trimester of pregnancy in inflammatory bowel disease. Gastro Hep Advances. 2022;1:785–91. - PMC - PubMed
    1. Russell MD, Dey M, Flint J, et al. Executive summary: british society for rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology. 2023;62(4):1370–87. - PMC - PubMed
    1. Zhong Z, Wang Y, Wang G, et al. Case report: tnf-alpha inhibitors to rescue pregnancy in women with potential pregnancy loss: a report of ten cases. Front Immunol. 2022;25(13): 900537. 10.3389/fimmu.2022.900537.PMID:35693803;PMCID:PMC9174430. - PMC - PubMed
    1. Mills BS, Dao KH, Tecson KM, et al. Perceptions of pregnancy and lactation from the pregnancy and lactation autoimmune network registry. J Rheumatol. 2020;47(1):149. - PubMed

Publication types